Monday, March 19, 2012
After six years of public
hearings and behind-the-scenes lobbying by academic, government and industry
infectious disease experts worried about drug-resistant pathogens, Congress is on
the verge of passing new incentives to develop anti-infective drugs.
The provisions of the
Generating Antibiotic Incentives Now (GAIN) Act (H.R. 2182) are incorporated in
draft legislation to reauthorize PDUFA produced by Republicans on the House
Energy and Commerce Committee and bipartisan leadership of the Senate Health,
Education, Labor and Pensions Committee (HELP).